GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$34.25 USD
-0.45 (-1.30%)
Updated Aug 18, 2022 04:00 PM ET
After-Market: $34.26 +0.01 (0.03%) 6:44 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Price, Consensus and EPS Surprise
GSK 34.25 -0.45(-1.30%)
Will GSK be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GSK based on the 1-3 month trading system that nearly triples the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GSK
GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance
Gilead (GILD) Announces Positive Data on Breast Cancer Drug
GSK: What are Zacks experts saying now?
Zacks Private Portfolio Services
PFE, GSK & Other Pharma Stocks Hit by Zantac Litigation
The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals
Biotech Stock Roundup: AMGN's Q2 Earnings, CCXI Acquisition & More Updates
Other News for GSK
Global Pharma Experts to Spotlight Digital Transformation at the 2022 ISPE Annual Meeting & Expo
GLOBAL BROKER RATINGS: Berenberg starts Poste Italiane with 'buy'
LONDON BROKER RATINGS: Jefferies likes AO, Berenberg lifts Devolver
UK dividends calendar - next 7 days
TOP NEWS: US FDA accepts GSK's new drug application for momelotinib